Online Pharmaceutical Schedule - June 2022


You are viewing June 2022. View May 2022 Schedule.

Vaccinations

Influenza vaccine         

Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) [Xpharm]

TICK Afluria Quad Junior (2022 formulation) 2631989 $11.00 per 1
  1. INFLUENZA VACCINE – child aged 6 months to 35 months

    is available each year for patients aged 6 months to 35 months who meet the following criteria, as set by Pharmac:

    1. have any of the following cardiovascular diseases

      1. ischaemic heart disease, or

      2. congestive heart failure, or

      3. rheumatic heart disease, or

      4. congenital heart disease, or

      5. cerebo-vascular disease; or

    2. have either of the following chronic respiratory diseases:

      1. asthma, if on a regular preventative therapy, or

      2. other chronic respiratory disease with impaired lung function; or

    3. have diabetes; or

    4. have chronic renal disease; or

    5. have any cancer, excluding basal and squamous skin cancers if not invasive; or

    6. have any of the following other conditions:

      1. autoimmune disease, or

      2. immune suppression or immune deficiency, or

      3. HIV, or

      4. transplant recipients, or

      5. neuromuscular and CNS diseases/disorders, or

      6. haemoglobinopathies, or

      7. on long term aspirin, or

      8. have a cochlear implant, or

      9. errors of metabolism at risk of major metabolic decompensation, or

      10. pre and post splenectomy, or

      11. down syndrome, or

    7. have been hospitalised for respiratory illness or have a history of significant respiratory illness;

    Unless meeting the criteria set out above, the following conditions are excluded from funding:

    1. asthma not requiring regular preventative therapy,

    2. hypertension and/or dyslipidaemia without evidence of end-organ disease.

  2. Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

 

 

 

 

 

 

 

 

Vaccinations

Influenza vaccine         

Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) - Only on a prescription - No patient co-payment payable

TICK Afluria Quad (2022 formulation) 2631970 $110.00 per 10
  1. INFLUENZA VACCINE – people 3 years and over

    is available each year for patients aged 3 years and over who meet the following criteria, as set by Pharmac:

    1. all people 65 years of age and over; or

    2. People 55 to 64 years of age (inclusive) and is Māori or any Pacific ethnicity; or

    3. people under 65 years of age who:

      1. have any of the following cardiovascular diseases:

        1. ischaemic heart disease, or

        2. congestive heart failure, or

        3. rheumatic heart disease, or

        4. congenital heart disease, or

        5. cerebo-vascular disease; or

      2. have either of the following chronic respiratory diseases:

        1. asthma, if on a regular preventative therapy, or

        2. other chronic respiratory disease with impaired lung function; or

      3. have diabetes; or

      4. have chronic renal disease; or

      5. have any cancer, excluding basal and squamous skin cancers if not invasive; or

      6. have any of the following other conditions:

        1. autoimmune disease, or

        2. immune suppression or immune deficiency, or

        3. HIV, or

        4. transplant recipients, or

        5. neuromuscular and CNS diseases/disorders, or

        6. haemoglobinopathies, or

        7. are children on long term aspirin, or

        8. have a cochlear implant, or

        9. errors of metabolism at risk of major metabolic decompensation, or

        10. pre and post splenectomy, or

        11. down syndrome, or

      7. are pregnant; or

    4. children 3 and 4 years of age (inclusive) who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

    Unless meeting the criteria set out above, the following conditions are excluded from funding:

    1. asthma not requiring regular preventative therapy,

    2. hypertension and/or dyslipidaemia without evidence of end-organ disease.

  2. Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

  3. Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.